Responses
Oncolytic and local immunotherapy
Original research
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
Compose a Response to This Article
Other responses
No responses have been published for this article.